Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -11.58% | 1.12% | 23.01% | 19.17% | 49.88% |
| Gross Profit | 11.58% | -1.12% | -23.01% | -19.17% | -49.88% |
| SG&A Expenses | 16.37% | 9.33% | 2.42% | -7.02% | -23.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.66% | 2.70% | 17.64% | 12.13% | 28.27% |
| Operating Income | 6.66% | -2.70% | -17.64% | -12.13% | -28.27% |
| Income Before Tax | -11.08% | 83.80% | 5.46% | -2.20% | 10.90% |
| Income Tax Expenses | -100.00% | -- | -- | -146.88% | -- |
| Earnings from Continuing Operations | -11.07% | 83.80% | 5.46% | -2.09% | 10.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.07% | 83.80% | 5.46% | -2.09% | 10.90% |
| EBIT | 6.66% | -2.70% | -17.64% | -12.13% | -28.27% |
| EBITDA | -- | -- | -- | -- | -27.88% |
| EPS Basic | 12.65% | 85.86% | 13.57% | 17.20% | -106.83% |
| Normalized Basic EPS | 18.25% | 86.35% | 9.52% | 38.08% | 75.55% |
| EPS Diluted | 12.65% | 85.86% | 13.57% | 17.20% | -106.83% |
| Normalized Diluted EPS | 18.25% | 86.35% | 9.52% | 38.08% | 75.55% |
| Average Basic Shares Outstanding | 35.88% | 18.72% | 32.93% | 65.05% | 254.05% |
| Average Diluted Shares Outstanding | 35.88% | 18.72% | 32.93% | 65.05% | 254.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |